JP2010519311A - 長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製およびその使用方法 - Google Patents

長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製およびその使用方法 Download PDF

Info

Publication number
JP2010519311A
JP2010519311A JP2009550992A JP2009550992A JP2010519311A JP 2010519311 A JP2010519311 A JP 2010519311A JP 2009550992 A JP2009550992 A JP 2009550992A JP 2009550992 A JP2009550992 A JP 2009550992A JP 2010519311 A JP2010519311 A JP 2010519311A
Authority
JP
Japan
Prior art keywords
acid
dpan
epimer
oil
dihydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009550992A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010519311A5 (OSRAM
Inventor
リンダ アーターバーン
ウィリアム バークレー
ビンディ ダンギ
ジェームズ フラット
ジャン リー
ダット ヴィンジャモーリ
エルスウィク メリー バン
Original Assignee
マーテック バイオサイエンシーズ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マーテック バイオサイエンシーズ コーポレーション filed Critical マーテック バイオサイエンシーズ コーポレーション
Publication of JP2010519311A publication Critical patent/JP2010519311A/ja
Publication of JP2010519311A5 publication Critical patent/JP2010519311A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/48—Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Birds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2009550992A 2007-02-20 2008-02-20 長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製およびその使用方法 Pending JP2010519311A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89070107P 2007-02-20 2007-02-20
PCT/US2008/054456 WO2008103753A2 (en) 2007-02-20 2008-02-20 Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same

Publications (2)

Publication Number Publication Date
JP2010519311A true JP2010519311A (ja) 2010-06-03
JP2010519311A5 JP2010519311A5 (OSRAM) 2011-04-07

Family

ID=39710725

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009550992A Pending JP2010519311A (ja) 2007-02-20 2008-02-20 長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製およびその使用方法

Country Status (5)

Country Link
US (1) US20110190389A1 (OSRAM)
EP (1) EP2120920A4 (OSRAM)
JP (1) JP2010519311A (OSRAM)
CN (1) CN101663031A (OSRAM)
WO (1) WO2008103753A2 (OSRAM)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015510517A (ja) * 2012-02-15 2015-04-09 アニダ ファーマ インコーポレイテッド 筋萎縮性側索硬化症の治療方法
JP2015140323A (ja) * 2014-01-29 2015-08-03 岩手県 Ｐｐａｒ活性化剤
JP2016520612A (ja) * 2013-05-30 2016-07-14 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 新規ｎ−３イムノリソルベント：構造及び作用
JP2022554152A (ja) * 2019-10-25 2022-12-28 ヌシード ニュートリショナル ユーエス インク． 濃縮多価不飽和脂肪酸組成物
WO2023090313A1 (ja) * 2021-11-16 2023-05-25 京都府公立大学法人 摂食量亢進用及び／又は食欲不振改善用組成物並びに一過性受容器電位アンキリン１を活性化するための組成物
US12337049B2 (en) 2021-05-26 2025-06-24 Amorepacific Corporation Method for whitening skin using composition for skin whitening
US12447117B2 (en) 2018-10-24 2025-10-21 Amorepacific Corporation Composition and method of enhancing skin barrier using the same

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009017802A1 (en) 2007-08-01 2009-02-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Nitro-fattyacid modulation of type ii diabetes
US20090326070A1 (en) 2008-05-01 2009-12-31 Complexa Inc. Vinyl substituted fatty acids
CN102099024B (zh) 2008-06-19 2015-11-25 犹他大学研究基金会 硝化脂质在毒性医疗疗法的副作用的治疗上的用途
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
WO2010033509A2 (en) * 2008-09-16 2010-03-25 The Brigham And Women's Hospital, Inc. 14-hydroxy-docosahexaenoic acid compounds
US8853437B2 (en) 2009-02-20 2014-10-07 The University Of Tokyo Anti-inflammatory compounds
FR2942964B1 (fr) * 2009-03-16 2012-08-17 Arkopharma Laboratoires Stimulateur metabolique des ppaps a base d'esters d'acides gras libres insatures, composition huileuse et complement alimentaire les contenant
EP2283839A1 (en) * 2009-06-30 2011-02-16 Institut National des Sciences Appliquées de Lyon Polyunsaturated hydroxylated molecule having an eze geometry and its use in therapy
JP2013500966A (ja) * 2009-07-31 2013-01-10 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 抗炎症剤としての脂肪酸
CA2781276A1 (en) 2009-10-02 2011-04-07 Complexa, Inc. Heteroatom containing substituted fatty acids
AU2012285806B2 (en) * 2011-07-21 2017-09-14 Dsm Ip Assets B.V. Fatty acid compositions
WO2013028501A1 (en) 2011-08-19 2013-02-28 The University Of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
JP6368645B2 (ja) * 2011-09-29 2018-08-01 ピーエルエックス オプコ インコーポレーテッド 胃腸管に沿った医薬の標的化放出のためのｐＨ依存性担体、それによる組成物、ならびにこれらの製造および使用
JP6399655B2 (ja) 2012-01-06 2018-10-03 オムセラ・ファーマシューティカルズ・インコーポレイテッド 遊離酸型のオメガ−３多価不飽和脂肪酸のｄｐａ濃縮組成物
EP2809317A4 (en) * 2012-02-03 2015-07-22 Univ Pittsburgh FATTY ACIDS AS ANTI-INFLAMMATORY ACTIVE SUBSTANCES
EP2846779A4 (en) 2012-05-07 2015-12-16 Omthera Pharmaceuticals Inc STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS
JP6370775B2 (ja) * 2012-05-10 2018-08-08 ソルテックス エヌエー エルエルシー 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油
HRP20230559T1 (hr) 2012-08-24 2023-09-15 Sun Pharmaceutical Industries Limited Oftalmička formulacija polioksil lipida ili polioksil masne kiseline i tretman očnih stanja
DK3097910T3 (da) * 2014-01-24 2020-07-27 Univ Kyoto Antiinflamatorisk middel indeholdende sjælden fedtsyre
US11135228B2 (en) * 2014-10-08 2021-10-05 The Brigham And Women's Hospital, Inc. Cysteinyl-proresolving mediators that promote resolution of infection and organ protection
HRP20210543T1 (hr) 2015-07-07 2021-05-14 H. Lundbeck A/S Inhibitori pde9 s imidazo triazinonskom okosnicom i imidazo pirazinonskom okosnicom za liječenje perifernih bolesti
JP6820312B2 (ja) * 2015-07-20 2021-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． アトルバスタチンにより増加し、炎症を消失させる新規な１３−シリーズのレゾルビンの解明
KR20170025977A (ko) * 2015-08-31 2017-03-08 재단법인차세대융합기술연구원 옥시리스 마리나로부터 분리된 신규 화합물
WO2017041094A1 (en) 2015-09-03 2017-03-09 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-hdha and 18- hepe and methods of using same
CN108430466A (zh) 2015-10-02 2018-08-21 康普莱克夏公司 使用治疗有效量的活化脂肪酸预防、治疗和逆转疾病
ES2974821T3 (es) 2015-11-10 2024-07-01 Sun Pharmaceutical Ind Ltd Formulaciones tópicas y usos de las mismas
CN109563517A (zh) * 2016-06-01 2019-04-02 加拿大国家研究委员会 菟葵脂肪酸延伸酶及其在脂肪酸生产中的用途
CN111989399B (zh) 2018-04-16 2024-07-12 韩国生命工学研究院 多不饱和脂肪酸的多羟基衍生物的制备方法
JP2021526134A (ja) 2018-05-25 2021-09-30 イマラ インク． ６−［（３Ｓ，４Ｓ）−４−メチル−ｌ−（ピリミジン−２−イルメチル）ピロリジン−３−イル］−３−テトラヒドロピラン−４−イル−７Ｈ−イミダゾ［ｌ，５−Ａ］ピラジン−８−オンの一水和物および結晶形態
EP3843737A4 (en) 2018-08-31 2022-06-01 Imara Inc. PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE
CN109161576B (zh) * 2018-09-26 2020-08-07 武汉中科光谷绿色生物技术有限公司 促进枯草芽孢杆菌发酵生产n-乙酰神经氨酸的方法
KR102673270B1 (ko) * 2018-10-15 2024-06-07 (주)아모레퍼시픽 피부장벽 강화용 조성물
US20230099067A1 (en) * 2020-02-18 2023-03-30 National University Corporation Hokkaido University Stable equivalent of resolvin e2
CN114354785B (zh) * 2021-12-22 2023-06-27 中国农业科学院油料作物研究所 一种基于保留指数结合化学衍生化质谱特征二级碎片的氧脂素综合定性方法
WO2024108603A1 (zh) * 2022-11-25 2024-05-30 中国科学院深圳先进技术研究院 基于粪便代谢物的神经退行性疾病标志物及其应用
FR3148365A1 (fr) * 2023-05-04 2024-11-08 Pierre Fabre Dermo-Cosmetique Oxylipines dans le traitement de la séborrhée et/ou de l’acné

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866046A (en) * 1988-05-31 1989-09-12 Top Laboratories, Inc. Low-dosage sublingual aspirin
US5102670A (en) * 1990-09-14 1992-04-07 Abraham Nader G Method for treating eye disorders by reducing 12(r)-hydroxyeicosatetraenoic acid and 12(r)-dihydroxyeicosatrienoic acid levels
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
US6887901B1 (en) * 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
GB9403857D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US5955496A (en) * 1996-08-13 1999-09-21 The Regents Of The University Of California Dihydroxy-oxy-eicosadienoates
PL190181B1 (pl) * 1996-10-11 2005-11-30 Scarista Ltd Zastosowanie oleju zawierającego kwas eikozapentaenowy (KEP) i/lub kwas stearydonowy (KS) oraz preparat farmaceutyczny zawierający olej
US6174695B1 (en) * 1997-08-12 2001-01-16 The Regents Of The University Of California Epoxide hydrolase inhibitor methods
DE19757414A1 (de) * 1997-12-23 1999-07-01 Nutricia Nv Fettmischung
US6596766B1 (en) * 1999-03-04 2003-07-22 Suntory Limited Utilization of material containing docosapentaenoic acid
CA2378968A1 (en) * 1999-07-07 2001-01-18 Kyowa Hakko Kogyo Co., Ltd. Process for producing hydroxylated fatty acid and o-lactones
ATE344226T1 (de) * 2000-02-16 2006-11-15 Brigham & Womens Hospital Aspirin-ausgelöste lipidmediatoren
DE10046541A1 (de) * 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
WO2002029018A2 (en) * 2000-10-06 2002-04-11 Michigan State University Divinyl ether synthase gene and protein, and uses thereof
CA2451116C (en) * 2001-05-14 2013-04-09 Martek Biosciences Corporation Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms
US7527935B2 (en) * 2002-03-19 2009-05-05 Mitsubishi Tanabe Pharma Corporation G-protein coupled receptor having eicosanoid as ligand and gene thereof
WO2003084305A2 (en) * 2002-04-01 2003-10-16 University Of Southern California Trihydroxy polyunsaturated eicosanoids
US7582785B2 (en) * 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
FR2843124B1 (fr) * 2002-08-02 2004-10-15 Goemar Lab Sa Procede de preparation d'acides gras polyinsatures libres et de leurs metabolites d'oxydation
EP2216318B1 (en) * 2002-08-12 2018-10-10 Brigham And Women's Hospital Resolvins: Biotemplates for therapeutic interventions
US20040166130A1 (en) * 2002-12-23 2004-08-26 L'oreal Lanolin-free cosmetic composition comprising a hydroxylated fatty acid aromatic ester
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
NZ555394A (en) * 2004-11-19 2010-07-30 Martek Biosciences Corp Oxylipins from long chain polyunsaturated fatty acids including docosapentaenoic acid and docosatetraenoic acid (DPA and DTA) and methods of making and using the same

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015510517A (ja) * 2012-02-15 2015-04-09 アニダ ファーマ インコーポレイテッド 筋萎縮性側索硬化症の治療方法
JP2016520612A (ja) * 2013-05-30 2016-07-14 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 新規ｎ−３イムノリソルベント：構造及び作用
JP2019163265A (ja) * 2013-05-30 2019-09-26 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 新規ｎ−３イムノリソルベント：構造及び作用
US11667598B2 (en) 2013-05-30 2023-06-06 The Brigham & Women's Hospital Inc. N-3 immunoresolvents: structures and actions
JP2015140323A (ja) * 2014-01-29 2015-08-03 岩手県 Ｐｐａｒ活性化剤
US12447117B2 (en) 2018-10-24 2025-10-21 Amorepacific Corporation Composition and method of enhancing skin barrier using the same
JP2022554152A (ja) * 2019-10-25 2022-12-28 ヌシード ニュートリショナル ユーエス インク． 濃縮多価不飽和脂肪酸組成物
US12337049B2 (en) 2021-05-26 2025-06-24 Amorepacific Corporation Method for whitening skin using composition for skin whitening
WO2023090313A1 (ja) * 2021-11-16 2023-05-25 京都府公立大学法人 摂食量亢進用及び／又は食欲不振改善用組成物並びに一過性受容器電位アンキリン１を活性化するための組成物

Also Published As

Publication number Publication date
WO2008103753A2 (en) 2008-08-28
EP2120920A2 (en) 2009-11-25
CN101663031A (zh) 2010-03-03
US20110190389A1 (en) 2011-08-04
EP2120920A4 (en) 2011-06-15
WO2008103753A3 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
JP2010519311A (ja) 長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製およびその使用方法
CN101102988B (zh) 来自长链多不饱和脂肪酸的氧脂素及其制备和使用方法
US7893106B2 (en) Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
US20090318394A1 (en) Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
EP1296923B3 (en) Aspirin-triggered lipid mediators
US20090320148A1 (en) Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same
JP2010519311A5 (OSRAM)
BRPI0311916B1 (pt) processo para a produção de um óleo microbiano compreendendo ácido araquidônico
AU2014358123B2 (en) Dihomo-gamma-linolenic acid-containing microbial oil and dihomo-gamma-linolenic acid-containing microbial biomass
JP7242769B2 (ja) 遊離多価不飽和脂肪酸含有組成物及びその製造方法
AU2011253846A1 (en) Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
NO348700B1 (en) Cetoleic acid composition
US20110027841A1 (en) Method for preparation of oxylipins
HK1105948B (en) Aspirin triggered lipid mediators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110218

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20120705